Physician profile
Amanda Berry
NPI 1386336071
$1,542.27
in general payments reported to CMS, 2019-2025
21 companies · $700 in 2025
The $700 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $168 · 2024: $674 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,542.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $344.36 | 2023-2025 | Minimed 780g |
| Amgen INC. | $318.02 | 2024-2025 | Tepezza |
| Lilly USA, LLC | $225.62 | 2023-2025 | Mounjaro, Jardiance |
| Revance Therapeutics, INC. | $133.33 | 2025 | Daxxify |
| Ascendis Pharma Endocrinology INC | $51.56 | 2023-2024 | |
| Recordati_rare_diseases_inc. | $49.67 | 2025 | Isturisa |
| Averitas Pharma INC. | $49.19 | 2023-2025 | Qutenza |
| Chiesi USA, INC. | $49.08 | 2024-2025 | Mycapssa |
| Inspire Medical Systems, INC. | $45.57 | 2024 | Inspire |
| Neurocrine Biosciences, INC. | $43.17 | 2024 | |
| Xeris Pharmaceuticals, INC. | $36.74 | 2023-2024 | Gvoke Hypopen, Recorlev |
| Galderma Laboratories, L.P. | $33.11 | 2025 | |
| Esperion Therapeutics, INC. | $28.90 | 2024-2025 | Nexletol |
| Corcept Therapeutics | $22.33 | 2024 | Korlym |
| Pfizer INC. | $20.39 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19.02 | 2024 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $18.53 | 2023 | Inpefa |
| Boston Scientific Corporation | $16.83 | 2024 | |
| Verity Pharmaceuticals INC. | $16.37 | 2024 | Tlando |
| Tolmar, INC. | $14.05 | 2024 | |
| Theracosbio, LLC | $6.43 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.